Letters, Statements & Analysis
AMCP communicates the importance of managed care pharmacy by collaborating with members to provide comments, analysis, and testimony to Congress and federal and state agencies on the impact of proposed regulations and laws on managed care pharmacy and patients.
On February 5, 2020, the Centers for Medicare & Medicaid Services (CMS) released the CY 2021 and 2022 Medicare Advantage and Medicare Prescription Drug Benefit Program Policy and Technical Rule, outlining proposed programmatic changes to the MA and Part D programs for two upcoming contract years. In a break from historic precedent, many of the program and policy changes that historically had been included in the Draft Call Letter were included in this proposed rule.
On February 5, 2020, the Centers for Medicare & Medicaid Services (CMS) released Part II of the Advance Notice of Methodological Changes for Calendar Year (CY) 2021 for Medicare Advantage (MA) Capitation Rates and Part C and Part D Payment Policies, outlining proposed payment changes and other requirements for plan sponsors participating in MA and the Part D program for the upcoming contract year.
The Academy of Managed Care Pharmacy (AMCP) thanks the Office of Inspector General (OIG) for the opportunity to provide written comments regarding the new proposed rulemaking on “Medicare and State Healthcare Programs: Fraud and Abuse; Revisions to Safe Harbors Under the Anti-Kickback Statute, and Civil Monetary Penalty Rules Regarding Beneficiary Inducements” published in the Federal Register on October 17, 2019.
In December 2016, AMCP applauded the passage of the 21st Century Cures Act as it included many provisions that will directly improve the health of Americans, from prompting new cures for cancer to combating opioid addiction.
AMCP expresses opinions on (SAMHSA’s) Confidentiality of Substance Use Disorder Patient Records Notice of Proposed Rulemaking (Proposed Rule).
The Academy of Managed Care Pharmacy (AMCP) thanks the Department of Health and Human Services (HHS) and the Centers for Medicare and Medicaid Services (CMS) for the opportunity to provide comments in response to the notice titled “Advance Summary of Methodological Changes for Calendar Year (CY) 2020 for Medicare Advantage (MA) Capitation Rates, Part C and Part D Payment Policies and 2020 Call Letter [CMS-2018-0154]” released on January 30, 2019.
The Academy of Managed Care Pharmacy (AMCP) thanks the Centers for Medicare and Medicaid Services (CMS) for the opportunity to provide comments in response to its proposed rule, “Medicare Program; Secure Electronic Prior Authorization for Medicare Part D [CMS-4819-P]” published in the Federal Register on June 19, 2019.
The Academy of Managed Care Pharmacy (AMCP) thanks the Centers for Medicare and Medicaid Services (CMS) for the opportunity to provide comments in response to its, “Request for Information; Reducing Administrative Burden To Put Patients Over Paperwork [CMS-6082-NC],” published in the Federal Register on June 11, 2019.
On July 23, Senate Finance Committee Chairman Chuck Grassley (R-Iowa) and Ranking Member Ron Wyden (D-OR) released the Chairman’s Mark of the Prescription Drug Pricing Reduction Act (PDPRA) of 2019, bipartisan legislation to reduce health care costs. AMCP will continue to engage with staff on the Finance committee on these provisions as we have with Members and staff on the Senate Health, Education, Labor, and Pensions (HELP) Committee.
The Academy of Managed Care Pharmacy (AMCP) is pleased to share our thoughts on the “Lower Health Care Costs Act” (“the Act”) as released on May 23, 2019 by the Committee on Health, Education, Labor and Pensions (“HELP Committee”).
The Academy of Managed Care Pharmacy (AMCP) thanks the Office of the National Coordinator for Health Information Technology (ONC) for the opportunity to provide comments in response to its proposed rule “21st Century Cures Act: Interoperability, Information Blocking, and the Health IT Certification Program” published in the Federal Register on March 4, 2019. AMCP appreciates ONC’s effort to remove barriers to interoperability and health information exchange.
The Academy of Managed Care Pharmacy (AMCP) thanks the Food and Drug Administration (FDA) for the opportunity to comment on its public hearing on Increasing Access and Facilitating the Efficient Development of Biosimilar and Interchangeable Insulin Products [FDA-2019-N-1132].
